Navigation Links
Isis Reports Financial Results and Highlights for First Quarter of 2008
Date:5/12/2008

estment and purchase option. Also contributing to the increase in operating expenses was $1.5 million of expenses associated with Isis' joint venture, Regulus, which are expected to increase over the year as Regulus increases its staffing and operations.

On a GAAP basis, Isis' operating expenses for the quarter ended March 31, 2008 were $30.2 million compared to $23.4 million for the same period in 2007, including non-cash compensation expense related to stock options of $3.8 million and $2.4 million for the quarters ended March 31, 2008 and 2007, respectively.

Ibis Biosciences, Inc.

Ibis' revenue for the quarter ended March 31, 2008 was $3.0 million compared to $1.6 million for the same period in 2007. As a result of the increased number of T5000 Biosensor System placements during fiscal year 2007, Ibis' commercial revenue of $1.2 million for the first quarter of 2008 was approximately double its commercial revenue of $631,000 in the first quarter of 2007. Commercial revenue consisted of revenue from sales of Ibis T5000 Biosensor Systems and assay kits, as well as revenue from Ibis' assay services business. Ibis' revenue from government contracts was $1.8 million for the first quarter of 2008, representing an increase of 89% over $945,000 in the first quarter of 2007, driven primarily by recently awarded contracts that support commercial as well as government applications of the T5000.

Excluding non-cash compensation expense related to stock options, operating expenses for Ibis were $6.4 million for the quarter ended March 31, 2008, compared to $4.3 million for the same period in 2007. The increase in operating expenses primarily reflects an increase in costs to support the growth of Ibis' commercial business and the cost to achieve milestones as part of the Abbott transaction. Ibis generated a loss from operations, excluding non-cash compensation expense related to stock options, of $3.4 million for the quarter ended March 31, 2008, com
'/>"/>

SOURCE Isis Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14

Related medicine news :

1. New Study Reports High Injury Rates for Hotel Workers, Even Higher Rates for Women and Nonwhites
2. Haemacure Reports Third Quarter 2007 Results
3. First-Ever List of the 5,000 Fastest-Growing Businesses Reports Total Revenue of $194.5 Billion
4. Consumer Reports Analysis: Drugs for Nerve Pain, Fibromyalgia Effective, But Not Always Best
5. MDS Reports Third Quarter 2007 Results
6. Allied Healthcare Reports Strong Fourth Quarter, Flat Net Income for Fiscal 2007 vs. 2006
7. AtriCure Reports First Human Implant of the Cosgrove-Gillinov Left Atrial Appendage Occlusion System
8. NMHC Reports Fourth Quarter and Fiscal Year 2007 Financial Results
9. Blue Cross and Blue Shield of Florida Reports Eighteenth Consecutive Year of Positive Performance
10. ReBuilder Medical Technologies, Inc. Reports International Sales Expansion
11. AdCare Health Systems, Inc. Reports Discontinuation of Definitive Merger Agreement with Family Home Health Services, Inc.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/31/2015)... Beckman Coulter is sponsoring a new educational webinar ... will highlight approaches used to extract more information from ... and will be broadcast live April 16, 2015 at ... for sedimentation data analysis have opened up ... range of technology sectors, including life science research, pharmaceutical ...
(Date:3/31/2015)... (PRWEB) March 31, 2015 The Denver ... District (RTD) are planning an array of public activities ... Signature Bus Tour and a Unity Parade and Rally ... for Transportation Day” – a national day of advocacy ... long-term, sustainable transportation funding. , The effort is being ...
(Date:3/31/2015)... An individual’s meniscus (cushion in the knee) ... leg providing stability, load bearing and preservation of the ... Day meeting of the American Orthopaedic Society for Sports ... the potential for biologic healing following a meniscus tear. ... of meniscus tears when a root repair is performed ...
(Date:3/31/2015)... March 31, 2015 The Oliver ... testosterone lawsuit claims, notes that filings for testosterone ... and other cardiovascular complications associated with testosterone therapy ... increasing at a steady pace. The website for ... where the testosterone lawsuits have been centralized, shows ...
(Date:3/31/2015)... March 31, 2015 The growing concern ... looking for options to protect themselves and their children. ... spring allergy season and recovering from an ugly flu ... relief to consumers – Aero One ( http://www.aero1UV.com ) ... only purges allergens from the air but also kills ...
Breaking Medicine News(10 mins):Health News:Beckman Coulter Webinar Series Presents Advances in Sedimentation Analysis 2Health News:Beckman Coulter Webinar Series Presents Advances in Sedimentation Analysis 3Health News:DRCOG & RTD Invite The Public To Stand Up For Transportation Funding 2Health News:DRCOG & RTD Invite The Public To Stand Up For Transportation Funding 3Health News:New Way to Evaluate Meniscus Tear Outcomes 2Health News:Testosterone Lawsuit Filings Rise To Over 1,200 In Multidistrict Litigation Pending In Northern Illinois Federal Court Reports The Oliver Law Group 2Health News:Testosterone Lawsuit Filings Rise To Over 1,200 In Multidistrict Litigation Pending In Northern Illinois Federal Court Reports The Oliver Law Group 3Health News:Startup Uses 3D-UV Technology to Take on Spring Allergies and Measles Virus 2Health News:Startup Uses 3D-UV Technology to Take on Spring Allergies and Measles Virus 3
... The deterioration of Hong Kong’s air quality has resulted in ... ,The deterioration of Hong Kong’s air quality ... with breathing problems. , , ,Researchers at ... such as sulphur dioxide, nitrogen dioxide and ozone of about ...
... The U.S. Food and Drug Administration (FDA) have approved a ... meats. This approval was given last month.// , ... Listeria. The approved spray is a combination of viruses that ... these foods before packaging and distribution. ,This virus ...
... A new study in the latest issue of the New ... help heart attack survivors. However more research is needed to ... effect of stem cells given to survivors of heart attacks ... hearts. Researchers looked at whether stem cells could repair the ...
... soothing guilt-free chocolate body wrap or deep relaxation with Indian ... a few years ago. ,But they are ... chattering classes, who seek a pampered lifestyle in the country's ... present to spend a few very feminine hours in one ...
... U.S. Food and Drug Administration on Wednesday reported having ... patch, cautioning users about the higher risk of blood ... Johnson’s commissioned study revealed that drug users faced two ... lungs compared to women taking traditional birth-control pills. ...
... experts, 80% of people suffering from severe chronic lung ... aware of it.// ,Chronic Bronchitis and Emphysema constitute ... to lung tissue by smoking can lead to the ... ,Professor Robert West, director of tobacco studies at ...
Cached Medicine News:Health News:Luxury Spas Ride Boom in Wellness Industry in Poland 2Health News:Contraceptive Patch Carries Risk of Blood clots 2Health News:80% of lung disease remains ‘undiagnosed’. 2
(Date:3/31/2015)... March 31, 2015  The growing threat posed ... a sense of urgency to the development of ... R&D costs and provide incentives for new drug ... Logo - http://photos.prnewswire.com/prnh/20150331/195565LOGO ... Product and Pipeline Analysis of the Antibacterial Drugs ...
(Date:3/30/2015)... 31, 2015 The Allen Institute for ... to define and advance the state-of-the-art digital reconstruction ... today, called BigNeuron, aims to create reliable high-throughput ... branches that make up individual neurons: a crucial ... information. "In our quest to ...
(Date:3/30/2015)... and BRISBANE, Calif., March 30, 2015 Shareholder ... the proposed acquisition of Hyperion Therapeutics, Inc. (NASDAQ: ... HZNP ).  On March 30, 2015, the two companies ... to which Horizon will acquire Hyperion.  Under the terms ... cash for each share of Hyperion common stock. ...
Breaking Medicine Technology:Development and Commercialization of Antibacterial Drugs to Speed Up 2Development and Commercialization of Antibacterial Drugs to Speed Up 3International Initiative Launched to Advance State-of-the-Art Digital Tracings of Neurons 2International Initiative Launched to Advance State-of-the-Art Digital Tracings of Neurons 3International Initiative Launched to Advance State-of-the-Art Digital Tracings of Neurons 4International Initiative Launched to Advance State-of-the-Art Digital Tracings of Neurons 5International Initiative Launched to Advance State-of-the-Art Digital Tracings of Neurons 6Robbins Arroyo LLP: Acquisition of Hyperion Therapeutics, Inc. (HPTX) by Horizon Pharma plc (HZNP) May Not Be in Shareholders' Best Interests 2Robbins Arroyo LLP: Acquisition of Hyperion Therapeutics, Inc. (HPTX) by Horizon Pharma plc (HZNP) May Not Be in Shareholders' Best Interests 3
... WESTMINSTER, Colo., Dec. 27 Allos,Therapeutics, Inc. (Nasdaq: ... Data,Monitoring Committee (DMC) has completed the pre-specified 65-patient,safety ... 2 PROPEL trial of,PDX (pralatrexate) in patients with ... recommended that the trial continue per the,protocol. This ...
... Traditional Approval -, YARDLEY, Pa., Dec. 21 ... Supplemental New Drug Application (sNDA) to the U.S. ... (PI) PREZISTA(TM),(darunavir) tablets, which seeks traditional approval and ... adults. The application includes 48-week data from two,Phase ...
Cached Medicine Technology:Interim Safety Analysis Supports Continuation of Allos Therapeutics' Pivotal Phase 2 PROPEL Trial of PDX in Patients with Peripheral T-cell Lymphoma 2Interim Safety Analysis Supports Continuation of Allos Therapeutics' Pivotal Phase 2 PROPEL Trial of PDX in Patients with Peripheral T-cell Lymphoma 3Interim Safety Analysis Supports Continuation of Allos Therapeutics' Pivotal Phase 2 PROPEL Trial of PDX in Patients with Peripheral T-cell Lymphoma 4Interim Safety Analysis Supports Continuation of Allos Therapeutics' Pivotal Phase 2 PROPEL Trial of PDX in Patients with Peripheral T-cell Lymphoma 5Supplemental New Drug Application for PREZISTA(TM) Submitted to U.S. Food and Drug Administration 2Supplemental New Drug Application for PREZISTA(TM) Submitted to U.S. Food and Drug Administration 3Supplemental New Drug Application for PREZISTA(TM) Submitted to U.S. Food and Drug Administration 4Supplemental New Drug Application for PREZISTA(TM) Submitted to U.S. Food and Drug Administration 5
... Shoulder Immobilizer A chest binder ... with contact closure. Humerus strap ... wrist cuff. Plastic stay. 1 ... strap may adjust for hand ...
... of shoulder, elbow, wrist, and hand. Appliance ... supported by the opposite shoulder. Abduction can ... arm support attaches to pillow wedge at ... attached anywhere along length of arm. Humerus ...
The Humeral Stabilizing System is a terrific option for immobilization of stable humeral fractures, stablesupracondular fractures, and biceps/triceps repairs....
... Evans AFO is designed to treat or ... with immobility such as hip displasia, foot ... calcaneus. A comfortable Kodel lining provides a ... The anti-rotation bar is easily rotated and ...
Medicine Products: